Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies
Therapeutic Advances in Respiratory Disease · 2024
DOI: 10.1177/17534666241232561 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2024. Verfasst von De-Yu Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NATCM’s Project of High-level Construction of Key TCM Disciplines.
Abstract (Originalsprache)
Background
Nintedanib and pirfenidone are preferred pharmacological therapies for patients with idiopathic pulmonary fibrosis (IPF). However, evidence favoring antifibrotic therapy in patients with non-IPF fibrosing interstitial lung diseases (ILD) is limited.
Objective
To investigate the effects of antifibrotic therapy on disease progression, all-cause mortality, and acute exacerbation (AE) risk in patients with non-IPF fibrosing ILDs.
Design
Meta-analysis. Data sources and methods: Electronic databases were searched for articles published before 28 February 2023. Studies that evaluated the efficacy of antifibrotic agents in patients with fibrosing ILDs were selected. The primary outcome was the disease progression risk, and the secondary outcomes included all-cause mortality and AE risk. The GRADE criteria were used for the certainty of evidence assessment.
Results
Nine studies with 1990 participants were included. Antifibrotic therapy reduced the rate of patients with disease progression (five trials with 1741 subjects; relative risk (RR), 0.56; 95% CI, 0.42–0.75; p < 0.0001; I 2 = 0; high-certainty evidence). Antifibrotic therapy did not significantly decrease all-cause mortality (nine trials with 1990 subjects; RR, 0.76; 95% CI, 0.55–1.03; p = 0.08; I 2 = 0; low-certainty evidence). However, in patients with progressive fibrosing ILDs (PF-ILD), antifibrotic therapy decreased all-cause mortality (four trials with 1100 subjects; RR, 0.69; 95% CI, 0.48–0.98; p = 0.04; I 2 = 0; low-certainty evidence).
Conclusion
Our study supports the use of antifibrotic agents in patients with PF-ILDs, which could slow disease progression and decrease all-cause mortality.
Trial registration
This study protocol was registered with PROSPERO (registration number: CRD42023411272).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
- Baoshan Branch, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Respiratory Medicine, Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, Nanjing 210029, China.
- School of Chinese Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210046, China.
ORCID-Profile: Yong Xu
Förderung
- NATCM’s Project of High-level Construction of Key TCM Disciplines
Zitieren
APA
Li, D. Y., Liu, X., Huang, J. Y., Hang, W. L., Yu, G. R., & Xu, Y. (2024). Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666241232561
Vancouver
Li DY, Liu X, Huang JY, Hang WL, Yu GR, Xu Y. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies. Therapeutic Advances in Respiratory Disease. 2024. doi:10.1177/17534666241232561
BibTeX
@article{Li2024,
author = {Li, De-Yu and Liu, Xin and Huang, Jing-Yi and Hang, Wen-Lu and Yu, Gu-Ran and Xu, Yong},
title = {Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2024},
doi = {10.1177/17534666241232561}
}
EUVIMED